StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research report report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Stock Down 7.8 %
Shares of RedHill Biopharma stock opened at $0.42 on Thursday. The stock’s fifty day moving average is $0.41 and its 200 day moving average is $0.48. RedHill Biopharma has a one year low of $0.26 and a one year high of $3.28.
Institutional Trading of RedHill Biopharma
A hedge fund recently raised its stake in RedHill Biopharma stock. Gagnon Securities LLC raised its stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 32.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 118,360 shares of the biotechnology company’s stock after purchasing an additional 28,771 shares during the period. Gagnon Securities LLC owned 0.40% of RedHill Biopharma worth $63,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.20% of the company’s stock.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Recommended Stories
- Five stocks we like better than RedHill Biopharma
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Trading Stocks: RSI and Why it’s Useful
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.